ActiveGRANT
DoW Peer Reviewed Cancer, Clinical Trial Award
Department of DefenseDept. of the Army -- USAMRAA
AI Overview
Accelerate cancer treatment breakthroughs through clinical trials testing new drugs, devices, and emerging therapies. This award funds rapid-cycle trials from proof-of-concept to phase III, addressing the urgent need to translate promising cancer interventions into patient care.
This summary is AI-generated from the official solicitation.
Key Details
Agency
Department of Defense
Funding Amount
—
Release Date
May 6, 2026
Due Date
October 5, 2026
Official Description
<p>Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed project...
View on official sourceChange History
Opportunity AddedMay 6, 2026 at 3:04 PM
DoW Peer Reviewed Cancer, Clinical Trial Award
New Grants.gov opportunity: DoW Peer Reviewed Cancer, Clinical Trial Award
Similar Opportunities
Get Alerts for Opportunities Like This
RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.
Start Free Trial